184 related articles for article (PubMed ID: 33427909)
21. Cord blood transplantation for adult patients with hematological malignancies.
Yamane T; Nakamae H; Hasegawa T; Terada Y; Hagihara K; Ohta K; Hino M
Osaka City Med J; 2005 Dec; 51(2):83-8. PubMed ID: 16617685
[TBL] [Abstract][Full Text] [Related]
22. Umbilical cord blood transplantation in adults: results of the prospective Cord Blood Transplantation (COBLT).
Cornetta K; Laughlin M; Carter S; Wall D; Weinthal J; Delaney C; Wagner J; Sweetman R; McCarthy P; Chao N
Biol Blood Marrow Transplant; 2005 Feb; 11(2):149-60. PubMed ID: 15682076
[TBL] [Abstract][Full Text] [Related]
23. Pre-engraftment syndrome after unrelated donor umbilical cord blood transplantation in patients with hematologic malignancies.
Wang X; Liu H; Li L; Geng L; Ding K; Liu X; Tong J; Zhu W; Sun Z
Eur J Haematol; 2012 Jan; 88(1):39-45. PubMed ID: 21933279
[TBL] [Abstract][Full Text] [Related]
24. Durable Chimerism and Long-Term Survival after Unrelated Umbilical Cord Blood Transplantation for Pediatric Hemophagocytic Lymphohistiocytosis: A Single-Center Experience.
Patel SA; Allewelt HA; Troy JD; Martin PL; Driscoll TA; Prasad VK; Kurtzberg J; Page KM; Parikh SH
Biol Blood Marrow Transplant; 2017 Oct; 23(10):1722-1728. PubMed ID: 28647558
[TBL] [Abstract][Full Text] [Related]
25. A comparison of post-transplantation cyclophosphamide versus antithymocyte-globulin in patients with hematological malignancies undergoing HLA-matched unrelated donor transplantation.
Lee MW; Yeon SH; Seo WH; Ryu H; Lee HJ; Yun HJ; Jo DY; Song IC
Medicine (Baltimore); 2020 Aug; 99(34):e21571. PubMed ID: 32846764
[TBL] [Abstract][Full Text] [Related]
26. Unrelated cord blood transplants in adults with hematologic malignancies.
Arcese W; Rocha V; Labopin M; Sanz G; Iori AP; de Lima M; Sirvent A; Busca A; Asano S; Ionescu I; Wernet P; Gluckman E;
Haematologica; 2006 Feb; 91(2):223-30. PubMed ID: 16461307
[TBL] [Abstract][Full Text] [Related]
27. Standardized, unrelated donor cord blood transplantation in adults with hematologic malignancies.
Sanz GF; Saavedra S; Planelles D; Senent L; Cervera J; Barragán E; Jiménez C; Larrea L; Martín G; Martínez J; Jarque I; Moscardó F; Plumé G; Andreu R; Regadera AI; García I; Mollá S; Solves P; de La Rubia J; Bolufer P; Benlloch L; Soler MA; Marty ML; Sanz MA
Blood; 2001 Oct; 98(8):2332-8. PubMed ID: 11588027
[TBL] [Abstract][Full Text] [Related]
28. Serious infection risk and immune recovery after double-unit cord blood transplantation without antithymocyte globulin.
Sauter C; Abboud M; Jia X; Heller G; Gonzales AM; Lubin M; Hawke R; Perales MA; van den Brink MR; Giralt S; Papanicolaou G; Scaradavou A; Small TN; Barker JN
Biol Blood Marrow Transplant; 2011 Oct; 17(10):1460-71. PubMed ID: 21310254
[TBL] [Abstract][Full Text] [Related]
29. [Clinical study of double units unrelated cord blood transplantation in adult patients with hematological malignancies].
Yin Y; Ren HY; Cen XN; Qiu ZX; Ou JP; Wang WS; Xu WL; Wang MJ; Wang LH; Li Y
Zhonghua Xue Ye Xue Za Zhi; 2008 Feb; 29(2):73-7. PubMed ID: 18681304
[TBL] [Abstract][Full Text] [Related]
30. Double umbilical cord blood transplantation in patients with hematologic malignancies using a reduced-intensity preparative regimen without antithymocyte globulin.
Ostronoff F; Milano F; Gooley T; Gutman JA; McSweeney P; Petersen FB; Sandmaier BM; Storb R; Delaney C
Bone Marrow Transplant; 2013 Jun; 48(6):782-6. PubMed ID: 23241738
[TBL] [Abstract][Full Text] [Related]
31. Graft-versus-host disease following allogeneic transplantation from HLA-identical sibling with antithymocyte globulin-based reduced-intensity preparative regimen.
Mohty M; Bay JO; Faucher C; Choufi B; Bilger K; Tournilhac O; Vey N; Stoppa AM; Coso D; Chabannon C; Viens P; Maraninchi D; Blaise D
Blood; 2003 Jul; 102(2):470-6. PubMed ID: 12649133
[TBL] [Abstract][Full Text] [Related]
32. Beneficial Role of Low-Dose Antithymocyte Globulin in Unrelated Stem Cell Transplantation for Adult Patients with Acquired Severe Aplastic Anemia: Reduction of Graft-versus-Host Disease and Improvement of Graft-versus-Host Disease-Free, Failure-Free Survival Rate.
Park SS; Kwak DH; Jeon YW; Yoon JH; Lee SE; Cho BS; Eom KS; Kim YJ; Kim HJ; Lee S; Min CK; Cho SG; Kim DW; Min WS; Lee JW
Biol Blood Marrow Transplant; 2017 Sep; 23(9):1498-1508. PubMed ID: 28554856
[TBL] [Abstract][Full Text] [Related]
33. A high antithymocyte globulin dose increases the risk of relapse after reduced intensity conditioning HSCT with unrelated donors.
Remberger M; Ringdén O; Hägglund H; Svahn BM; Ljungman P; Uhlin M; Mattsson J
Clin Transplant; 2013; 27(4):E368-74. PubMed ID: 23701240
[TBL] [Abstract][Full Text] [Related]
34. Outcomes of Adolescents and Young Adults Compared with Children with Acute Leukemia after Single-Unit Unrelated Cord Blood Transplantation Using Myeloablative Conditioning without Antithymocyte Globulin.
Zhang X; Liu H; Zheng C; Tang B; Zhu X; Wan X; Tong J; Yao W; Song K; Sun Z
Acta Haematol; 2021; 144(5):569-579. PubMed ID: 33849019
[TBL] [Abstract][Full Text] [Related]
35. Busulfan/melphalan/antithymocyte globulin followed by unrelated donor cord blood transplantation for treatment of infant leukemia and leukemia in young children: the Cord Blood Transplantation study (COBLT) experience.
Wall DA; Carter SL; Kernan NA; Kapoor N; Kamani NR; Brochstein JA; Frangoul H; Goyal RK; Horan JT; Pietryga D; Wagner JE; Kurtzberg J;
Biol Blood Marrow Transplant; 2005 Aug; 11(8):637-46. PubMed ID: 16041314
[TBL] [Abstract][Full Text] [Related]
36. Comparison of outcomes after two standards-of-care reduced-intensity conditioning regimens and two different graft sources for allogeneic stem cell transplantation in adults with hematologic diseases: a single-center analysis.
Le Bourgeois A; Mohr C; Guillaume T; Delaunay J; Malard F; Loirat M; Peterlin P; Blin N; Dubruille V; Mahe B; Gastinne T; Le Gouill S; Moreau P; Mohty M; Planche L; Lode L; Bene MC; Chevallier P
Biol Blood Marrow Transplant; 2013 Jun; 19(6):934-9. PubMed ID: 23523970
[TBL] [Abstract][Full Text] [Related]
37. Double-unit cord blood transplantation after myeloablative conditioning for patients with hematologic malignancies: a multicenter phase II study in Japan.
Kai S; Wake A; Okada M; Kurata M; Atsuta Y; Ishikawa J; Nakamae H; Aotsuka N; Kasai M; Misawa M; Taniguchi S; Kato S
Biol Blood Marrow Transplant; 2013 May; 19(5):812-9. PubMed ID: 23416856
[TBL] [Abstract][Full Text] [Related]
38. Prospective multicenter study of single-unit cord blood transplantation with myeloablative conditioning for adult patients with high-risk hematologic malignancies.
Mori T; Tanaka M; Kobayashi T; Ohashi K; Fujisawa S; Yokota A; Fujita H; Nakaseko C; Sakura T; Nannya Y; Takahashi S; Kanamori H; Kanda Y; Sakamaki H; Okamoto S;
Biol Blood Marrow Transplant; 2013 Mar; 19(3):486-91. PubMed ID: 23253560
[TBL] [Abstract][Full Text] [Related]
39. [Unrelated cord blood transplantation for the treatment of hematological malignancies].
Ren HY; Zhang YC; Huang XJ; Xu LP; Liu KY; Li D; Guo NL; Lu DP
Zhonghua Xue Ye Xue Za Zhi; 2003 Feb; 24(2):82-5. PubMed ID: 12697102
[TBL] [Abstract][Full Text] [Related]
40. Sufficient Immunosuppression with Thymoglobulin Is Essential for a Successful Haplo-Myeloid Bridge in Haploidentical-Cord Blood Transplantation.
Lindemans CA; Te Boome LC; Admiraal R; Jol-van der Zijde EC; Wensing AM; Versluijs AB; Bierings MB; Kuball J; Boelens JJ
Biol Blood Marrow Transplant; 2015 Oct; 21(10):1839-45. PubMed ID: 26119367
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
